Climb Bio, Inc. ((CLYM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Climb Bio, Inc. (CLYM) is currently conducting a Phase 1 study titled A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous and Intravenous Injections of Budoprutug (TNT119) in Normal Healthy Volunteers. The study aims to assess the safety and tolerability of budoprutug injections in healthy volunteers, marking a significant step in the drug’s development.
The intervention being tested is Budoprutug, administered either subcutaneously or intravenously. This drug is designed to evaluate its safety profile and pharmacological effects in humans.
The study employs a randomized, double-blind, placebo-controlled design with a sequential intervention model. Both participants and investigators are masked to ensure unbiased results, focusing on basic scientific understanding.
The study began on July 21, 2025, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on August 15, 2025, indicating active recruitment.
This update could influence Climb Bio’s stock performance positively, as successful early-phase trials often boost investor confidence. However, the competitive landscape in the biotechnology sector means that investors should remain cautious and informed about industry trends.
The study is ongoing, with further details available on the ClinicalTrials portal.